PL4053128T3 - Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu - Google Patents

Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu

Info

Publication number
PL4053128T3
PL4053128T3 PL22152688.2T PL22152688T PL4053128T3 PL 4053128 T3 PL4053128 T3 PL 4053128T3 PL 22152688 T PL22152688 T PL 22152688T PL 4053128 T3 PL4053128 T3 PL 4053128T3
Authority
PL
Poland
Prior art keywords
pyrazolo
difluorophenyl
pyrazol
pyrrolidin
treating cancer
Prior art date
Application number
PL22152688.2T
Other languages
English (en)
Inventor
Kollol Pal
Stephane Ciblat
Vincent Albert
Nicolas BRUNEAU-LATOUR
Jonathan BOUDREAULT
Original Assignee
Biohaven Therapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd. filed Critical Biohaven Therapeutics Ltd.
Publication of PL4053128T3 publication Critical patent/PL4053128T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL22152688.2T 2017-12-15 2018-12-12 Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu PL4053128T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762599490P 2017-12-15 2017-12-15

Publications (1)

Publication Number Publication Date
PL4053128T3 true PL4053128T3 (pl) 2025-01-27

Family

ID=65139120

Family Applications (2)

Application Number Title Priority Date Filing Date
PL22152688.2T PL4053128T3 (pl) 2017-12-15 2018-12-12 Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu
PL18836977T PL3724191T3 (pl) 2017-12-15 2018-12-12 Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18836977T PL3724191T3 (pl) 2017-12-15 2018-12-12 Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu

Country Status (26)

Country Link
US (4) US11230546B2 (pl)
EP (2) EP3724191B9 (pl)
JP (1) JP7321183B2 (pl)
KR (1) KR102738182B1 (pl)
CN (1) CN111819179B (pl)
AU (1) AU2018383571B2 (pl)
CA (1) CA3084814A1 (pl)
DK (2) DK3724191T3 (pl)
EA (1) EA202091475A1 (pl)
ES (2) ES2908773T3 (pl)
FI (1) FI4053128T3 (pl)
HR (2) HRP20241426T1 (pl)
HU (2) HUE059313T2 (pl)
IL (1) IL275059B2 (pl)
LT (2) LT4053128T (pl)
MX (1) MX2020006293A (pl)
PL (2) PL4053128T3 (pl)
PT (2) PT4053128T (pl)
RS (1) RS66124B1 (pl)
SA (1) SA520412192B1 (pl)
SG (1) SG11202005237SA (pl)
SI (2) SI4053128T1 (pl)
SM (1) SMT202400435T1 (pl)
TW (1) TWI848925B (pl)
WO (1) WO2019118584A1 (pl)
ZA (2) ZA202003483B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241426T1 (hr) 2017-12-15 2024-12-20 Biohaven Therapeutics Ltd. Derivati 5-(2-(2,5-difluorofenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pirimidina i srodni spojevi kao inhibitori trk kinaze za liječenje raka
GB201813791D0 (en) * 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
JP7209415B2 (ja) * 2019-03-19 2023-01-20 セントラル チャイナ ノーマル ユニバーシティ ピラゾロピリミジン化合物、医薬組成物、及びその使用
CN111718350B (zh) * 2019-03-19 2021-04-13 华中师范大学 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用
CN111848626B (zh) * 2019-04-30 2021-11-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业(成都)有限公司 杂芳基稠环化合物、其制备方法及应用
CN115515591B (zh) * 2020-04-15 2024-09-27 派拉米德生物科学公司 用于制备酪氨酸受体激酶抑制剂的方法
CN114437077B (zh) * 2020-11-04 2024-01-30 浙江同源康医药股份有限公司 用作激酶抑制剂的化合物及其应用
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
KR102541026B1 (ko) * 2020-11-11 2023-06-12 주식회사 한독 Trk 억제제 화합물의 제조 방법
AU2021403015A1 (en) * 2020-12-15 2023-08-03 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
ES2548135T3 (es) * 2008-05-13 2015-10-14 Novartis Ag Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
WO2010048314A1 (en) 2008-10-22 2010-04-29 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
WO2010051549A1 (en) 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011029027A1 (en) 2009-09-03 2011-03-10 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012125668A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
PT2834243T (pt) * 2012-03-09 2018-08-01 Lexicon Pharmaceuticals Inc Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização
US20140288043A1 (en) 2013-03-19 2014-09-25 Genentech, Inc. Pyrazolopyridine compounds
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
FR3029769A1 (fr) * 2014-12-10 2016-06-17 Tornier Sa Kit pour une prothese d'epaule
EP3233863B1 (en) * 2014-12-15 2024-04-10 CMG Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
JP6475084B2 (ja) 2015-05-21 2019-02-27 臼井国際産業株式会社 トルクセンサ用シャフトの製造設備およびその製造方法
DE102016219374B4 (de) 2016-10-06 2018-06-14 Siemens Aktiengesellschaft Langzeitstabile und stoffschlüssige Strompfadverbindung für Nieder-, Mittelspannungs- und/oder Hochspannungsanlagen bzw. –Schaltgeräte mittels Nanomaterialien
HRP20241426T1 (hr) 2017-12-15 2024-12-20 Biohaven Therapeutics Ltd. Derivati 5-(2-(2,5-difluorofenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pirimidina i srodni spojevi kao inhibitori trk kinaze za liječenje raka
CN112398593B (zh) 2019-08-13 2024-08-16 上海朗帛通信技术有限公司 一种被用于无线通信的节点中的方法和装置
CN115515591B (zh) 2020-04-15 2024-09-27 派拉米德生物科学公司 用于制备酪氨酸受体激酶抑制剂的方法

Also Published As

Publication number Publication date
PT4053128T (pt) 2024-10-15
ES2908773T3 (es) 2022-05-03
ZA202205900B (en) 2023-11-29
US20210094956A1 (en) 2021-04-01
MX2020006293A (es) 2020-12-03
EP4053128B8 (en) 2024-10-02
CN111819179B (zh) 2023-09-01
EP4053128A1 (en) 2022-09-07
DK4053128T3 (da) 2024-10-21
US11230546B2 (en) 2022-01-25
TWI848925B (zh) 2024-07-21
KR20200099557A (ko) 2020-08-24
EA202091475A1 (ru) 2020-09-09
TW201936194A (zh) 2019-09-16
ES2992993T3 (en) 2024-12-20
EP3724191B1 (en) 2022-01-26
PT3724191T (pt) 2022-03-07
AU2018383571A1 (en) 2020-06-18
US12486276B2 (en) 2025-12-02
DK3724191T3 (da) 2022-03-14
EP3724191B9 (en) 2022-05-18
JP7321183B2 (ja) 2023-08-04
SG11202005237SA (en) 2020-07-29
CN111819179A (zh) 2020-10-23
PL3724191T3 (pl) 2022-04-25
US20230124248A1 (en) 2023-04-20
IL275059B2 (en) 2023-11-01
US20220235055A1 (en) 2022-07-28
BR112020011775A2 (pt) 2020-11-17
SMT202400435T1 (it) 2025-01-14
HRP20241426T1 (hr) 2024-12-20
EP3724191A1 (en) 2020-10-21
US11739096B2 (en) 2023-08-29
US20240246976A1 (en) 2024-07-25
KR102738182B1 (ko) 2024-12-03
LT4053128T (lt) 2024-11-25
ZA202003483B (en) 2023-01-25
HUE059313T2 (hu) 2022-11-28
AU2018383571B2 (en) 2023-09-21
HRP20220464T1 (hr) 2022-05-27
EP4053128B1 (en) 2024-08-21
CA3084814A1 (en) 2019-06-20
RS66124B1 (sr) 2024-11-29
LT3724191T (lt) 2022-04-25
FI4053128T3 (fi) 2024-10-25
SA520412192B1 (ar) 2022-08-11
SI4053128T1 (sl) 2025-03-31
JP2021506954A (ja) 2021-02-22
WO2019118584A1 (en) 2019-06-20
SI3724191T1 (sl) 2022-06-30
IL275059B1 (en) 2023-07-01
IL275059A (en) 2020-07-30
HUE069285T2 (hu) 2025-02-28

Similar Documents

Publication Publication Date Title
ZA202003483B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
IL280701A (en) History of 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3,2-dichlorophenyl)-2-methylpyrimidin-4(H3)-one and compounds related as PTPN11 (SHP2) inhibitors for cancer treatment
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
IL265918A (en) Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors
HUE052454T2 (hu) CDK4 inhibitorok 2-((5-(1-(3-(metilszulfonil)propil)piperidin-4-il)piridin-2-il)amino)-pirido[2,3-D]pirimidin-7(8H)-on származékok és rokonvegyületek tumorok kezelésére
PT3458456T (pt) Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
IL288529A (en) History of imidazo[2,1-c]pyrimidine as prc2 inhibitors for cancer therapy
PH12019500478A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
HK40029595A (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
PT3621966T (pt) Derivados de pirazole[1,5-a]pirimidina como inibidores de cinase jak